Menlo Park, CA, United States of America

Richard S Lilly

This inventor holds 44 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Glaucoma Treatment. Top assignees: Shifamed Holdings, LLC, Transcend Medical, Inc., Novartis Ag. Active years: 2000-2026.

USPTO Granted Patents = 44 

% Patents Active = 97.7

 

 

Average Co-Inventor Count = 4.1

ph-index = 14

Forward Citations = 996(Granted Patents)


Location History:

  • Menlo Park, CA (US) (2014 - 2021)
  • San Jose, CA (US) (2000 - 2024)

Company Filing History:


Years Active: 2000-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Glaucoma Treatment
Adjustable Flow Shunts
Medical Devices
Fluid Delivery
Intraocular Shunts
Aneurysm Treatment
Ocular Implant
Shunting Systems
Gonio Lens
Flow Control
Cannula
Shape Change Capabilities
44 patents (USPTO):Explore Patents

Title: The Innovative Journey of Richard S. Lilly

Introduction: Richard S. Lilly, a distinguished inventor based in Menlo Park, CA, has made significant contributions to the field of technology and innovation.

Latest Patents: Richard S. Lilly holds several patents in various technological domains, showcasing his continuous commitment to pushing the boundaries of innovation.

Career Highlights: With a career spanning over two decades, Richard S. Lilly has been at the forefront of groundbreaking inventions, revolutionizing the way we interact with technology on a daily basis.

Collaborations: Throughout his career, Richard S. Lilly has collaborated with leading tech companies, research institutions, and universities to further advance the realm of innovation and bring cutting-edge solutions to life.

Conclusion: Richard S. Lilly's passion for innovation and his relentless drive to create have solidified his position as a trailblazer in the world of technology, inspiring future generations of inventors to dream big and push the limits of what is possible.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…